ClinicalTrials.Veeva

Menu

Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Rigshospitalet logo

Rigshospitalet

Status

Withdrawn

Conditions

Cardiac Sarcoidosis

Treatments

Drug: Cu-64 DOTATATE

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Group A: Suspected cardiac sarcoidosis Group B: Known cardiac sarcoidosis, clinical follow-up Group C: Myocarditis or dilated cardiomyopathy (Non-cardiac sarcoidosis)

Exclusion criteria

Infection Pregnancy Severe claustrophobia Weight >140 kg

Trial design

0 participants in 3 patient groups

Suspected cardiac sarcoidosis
Description:
Cu-64 DOTATATE PET/CT or PET/MRI
Treatment:
Drug: Cu-64 DOTATATE
Known cardiac sarcoidosis
Description:
Cu-64 DOTATATE PET/CT or PET/MRI
Treatment:
Drug: Cu-64 DOTATATE
Other inflammatory cardiac disease
Description:
Cu-64 DOTATATE PET/CT or PET/MRI
Treatment:
Drug: Cu-64 DOTATATE

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems